Your browser doesn't support javascript.
loading
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.
Makawita, Shalini; K Abou-Alfa, Ghassan; Roychowdhury, Sameek; Sadeghi, Saeed; Borbath, Ivan; Goyal, Lipika; Cohn, Allen; Lamarca, Angela; Oh, Do-Youn; Macarulla, Teresa; T Shroff, Rachna; Howland, Michael; Li, Ai; Cho, Terry; Pande, Amit; Javle, Milind.
Afiliação
  • Makawita S; Division of Cancer Medicine, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
  • K Abou-Alfa G; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Roychowdhury S; Department of Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
  • Sadeghi S; Division of Medical Oncology, Department of Internal Medicine, The James Cancer Hospital & Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.
  • Borbath I; Department of Medicine, Division of Hematology/Oncology, University of California, Los Angeles, CA 90404, USA.
  • Goyal L; Department of Gastroenterology & Digestive Oncology, Cliniques Universitaires Saint-Luc & Université Catholique de Louvain, Brussels, Belgium.
  • Cohn A; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Lamarca A; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
  • Oh DY; Rocky Mountain Cancer Center & US Oncology Research, Denver, CO 80218, USA.
  • Macarulla T; Department of Medical Oncology, The Christie NHS Foundation Trust, Division of Cancer Sciences, University of Manchester, Manchester, UK.
  • T Shroff R; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Howland M; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology & IOB quirón, Barcelona, Spain.
  • Li A; Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ 85724, USA.
  • Cho T; QED Therapeutics, San Francisco, CA, USA.
  • Pande A; QED Therapeutics, San Francisco, CA, USA.
  • Javle M; QED Therapeutics, San Francisco, CA, USA.
Future Oncol ; 16(30): 2375-2384, 2020 Oct.
Article em En | MEDLINE | ID: mdl-32580579
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirimidinas / Neoplasias dos Ductos Biliares / Proteínas de Fusão Oncogênica / Protocolos Clínicos / Colangiocarcinoma / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirimidinas / Neoplasias dos Ductos Biliares / Proteínas de Fusão Oncogênica / Protocolos Clínicos / Colangiocarcinoma / Receptor Tipo 2 de Fator de Crescimento de Fibroblastos Tipo de estudo: Clinical_trials / Guideline Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article